Extract from the Clinical Evaluation Report for conjugated ...

Modifiable risk factors that could exacerbate adverse effects of treatment should be addressed prior to and during treatment (e.g., smoking cessation, weight, illicit drug use) Ongoing monitoring is an essential component of the safe use of treatment. Note: The use of cross-sex hormones for transgender patients is non-FDA approved, or off-label. ................
................